TY - JOUR
T1 - Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load
T2 - A controlled study of 3 IL-2 regimens with antiviral drug therapy
AU - Tambussi, G.
AU - Ghezzi, S.
AU - Nozza, S.
AU - Vallanti, G.
AU - Magenta, L.
AU - Guffanti, M.
AU - Brambilla, A.
AU - Vicenzi, E.
AU - Carrera, P.
AU - Racca, S.
AU - Soldini, L.
AU - Gianotti, N.
AU - Murone, M.
AU - Veglia, F.
AU - Poli, G.
AU - Lazzarin, A.
PY - 2001/5/15
Y1 - 2001/5/15
N2 - To evaluate the safety and efficacy of 3 regimens of intermittent subcutaneous (sc) interleukin (IL)-2 in a phase 2 study, 61 antiviral drug-experienced human immunodeficiency virus (HIV)-positive patients were randomly assigned to one of the following study arms: Antiretroviral therapy (ART) plus IL-2 (12 million IU [MIU] by continuous intravenous infusion, followed by 7.5 MIU twice a day, sc, every 8 weeks); ART plus IL-2 (7.5 MIU twice a day, sc, every 8 weeks); ART plus IL-2 (3 MIU twice a day, sc, every 4 weeks); or ART alone. A significant increase of circulating CD4 cells was observed in IL-2-treated subjects, compared with those given ART alone. Low doses of IL-2 were better tolerated. Despite the incomplete suppression of viral replication, IL-2 with ART did not increase either plasma viremia or cell-associated HIV DNA levels. Low doses of intermittent sc IL-2 induced a stable increase of peripheral CD4 cells that was indistinguishable from those associated with higher, less well-tolerated doses of IL-2.
AB - To evaluate the safety and efficacy of 3 regimens of intermittent subcutaneous (sc) interleukin (IL)-2 in a phase 2 study, 61 antiviral drug-experienced human immunodeficiency virus (HIV)-positive patients were randomly assigned to one of the following study arms: Antiretroviral therapy (ART) plus IL-2 (12 million IU [MIU] by continuous intravenous infusion, followed by 7.5 MIU twice a day, sc, every 8 weeks); ART plus IL-2 (7.5 MIU twice a day, sc, every 8 weeks); ART plus IL-2 (3 MIU twice a day, sc, every 4 weeks); or ART alone. A significant increase of circulating CD4 cells was observed in IL-2-treated subjects, compared with those given ART alone. Low doses of IL-2 were better tolerated. Despite the incomplete suppression of viral replication, IL-2 with ART did not increase either plasma viremia or cell-associated HIV DNA levels. Low doses of intermittent sc IL-2 induced a stable increase of peripheral CD4 cells that was indistinguishable from those associated with higher, less well-tolerated doses of IL-2.
UR - http://www.scopus.com/inward/record.url?scp=0035873085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035873085&partnerID=8YFLogxK
U2 - 10.1086/320188
DO - 10.1086/320188
M3 - Article
C2 - 11319683
AN - SCOPUS:0035873085
VL - 183
SP - 1476
EP - 1484
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 10
ER -